Human placental cell and tissue uptake of doxorubicin and its liposomal formulations
•Human placental cell and tissue uptake of doxorubicin was significant.•Doxorubicin crossed placenta at low levels within 4-h human placental perfusion.•Pegylated liposomal doxorubicin was weakly taken up by human placental cells.•Pegylated liposomal doxorubicin did not cross human placenta in 4-h p...
Gespeichert in:
| Veröffentlicht in: | Toxicology letters 2015-12, Vol.239 (2), p.108-114 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 114 |
|---|---|
| container_issue | 2 |
| container_start_page | 108 |
| container_title | Toxicology letters |
| container_volume | 239 |
| creator | Soininen, Suvi K. Repo, Jenni K. Karttunen, Vesa Auriola, Seppo Vähäkangas, Kirsi H. Ruponen, Marika |
| description | •Human placental cell and tissue uptake of doxorubicin was significant.•Doxorubicin crossed placenta at low levels within 4-h human placental perfusion.•Pegylated liposomal doxorubicin was weakly taken up by human placental cells.•Pegylated liposomal doxorubicin did not cross human placenta in 4-h perfusion.
The anticancer drug doxorubicin and its liposomal formulations are in clinical use, doxorubicin also during pregnancy. However, little is known about how doxorubicin and its liposomal formulations are taken up by placental cells and whether they can cross human placenta. We therefore investigated quantitative cellular uptake and toxicity of doxorubicin and its two liposomal formulations, pH-sensitive liposomal doxorubicin (L-DOX) and commercially available pegylated liposomal doxorubicin (PL-DOX), in human placental choriocarcinoma (BeWo) cells. PL-DOX showed significantly lower cellular uptake and toxicity compared with doxorubicin and L-DOX. In preliminary studies with human placental perfusion, PL-DOX did not cross the placenta at all in 4h, whereas doxorubicin and L-DOX crossed the placenta at low levels (max 12% of the dose). Furthermore, PL-DOX did not accumulate in placental tissue while doxorubicin did (up to 70% of the dose). Surface pegylation probably explains the low placental cell and tissue uptake of PL-DOX. Formulation of doxorubicin thus seems to enable a decrease of fetal exposure. |
| doi_str_mv | 10.1016/j.toxlet.2015.09.011 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1762107653</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378427415300515</els_id><sourcerecordid>1762107653</sourcerecordid><originalsourceid>FETCH-LOGICAL-c428t-9ce57a0cd96eb23f1c204a7d01fd7309ac6647c2975a283a94de62d57245f81d3</originalsourceid><addsrcrecordid>eNqNkE1P3DAURa2qqAy0_6BCWXaT8PwRO94gVQgKEhIbWFse-0XyNImD7SD678kwlGXV1duce6_eIeQ7hYYClee7psSXAUvDgLYN6AYo_UQ2tFO65lTqz2QDXHW1YEock5OcdwAghWy_kGMmecclpxvycLOMdqrmwTqcih0qh8NQ2clXJeS8YLXMxf7GKvaVjy8xLdvgwvQGhJKrIcwxx3HN9TGNy2BLiFP-So56O2T89n5PyeP11cPlTX13_-v28udd7QTrSq0dtsqC81rilvGeOgbCKg-094qDtk5KoRzTqrWs41YLj5L5VjHR9h31_JT8OPTOKT4tmIsZQ94_YCeMSzZUSUZByZb_B8qUXIcAVlQcUJdizgl7M6cw2vTHUDB79WZnDurNXr0BbVb1a-zsfWHZjug_Qn9dr8DFAcBVyXPAZLILODn0IaErxsfw74VX8wyXNQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1727697500</pqid></control><display><type>article</type><title>Human placental cell and tissue uptake of doxorubicin and its liposomal formulations</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Soininen, Suvi K. ; Repo, Jenni K. ; Karttunen, Vesa ; Auriola, Seppo ; Vähäkangas, Kirsi H. ; Ruponen, Marika</creator><creatorcontrib>Soininen, Suvi K. ; Repo, Jenni K. ; Karttunen, Vesa ; Auriola, Seppo ; Vähäkangas, Kirsi H. ; Ruponen, Marika</creatorcontrib><description>•Human placental cell and tissue uptake of doxorubicin was significant.•Doxorubicin crossed placenta at low levels within 4-h human placental perfusion.•Pegylated liposomal doxorubicin was weakly taken up by human placental cells.•Pegylated liposomal doxorubicin did not cross human placenta in 4-h perfusion.
The anticancer drug doxorubicin and its liposomal formulations are in clinical use, doxorubicin also during pregnancy. However, little is known about how doxorubicin and its liposomal formulations are taken up by placental cells and whether they can cross human placenta. We therefore investigated quantitative cellular uptake and toxicity of doxorubicin and its two liposomal formulations, pH-sensitive liposomal doxorubicin (L-DOX) and commercially available pegylated liposomal doxorubicin (PL-DOX), in human placental choriocarcinoma (BeWo) cells. PL-DOX showed significantly lower cellular uptake and toxicity compared with doxorubicin and L-DOX. In preliminary studies with human placental perfusion, PL-DOX did not cross the placenta at all in 4h, whereas doxorubicin and L-DOX crossed the placenta at low levels (max 12% of the dose). Furthermore, PL-DOX did not accumulate in placental tissue while doxorubicin did (up to 70% of the dose). Surface pegylation probably explains the low placental cell and tissue uptake of PL-DOX. Formulation of doxorubicin thus seems to enable a decrease of fetal exposure.</description><identifier>ISSN: 0378-4274</identifier><identifier>EISSN: 1879-3169</identifier><identifier>DOI: 10.1016/j.toxlet.2015.09.011</identifier><identifier>PMID: 26383631</identifier><language>eng</language><publisher>Netherlands: Elsevier Ireland Ltd</publisher><subject>Antibiotics, Antineoplastic - administration & dosage ; Antibiotics, Antineoplastic - pharmacokinetics ; BeWo cells ; Cell Line, Tumor ; Cell Survival ; Cellular ; Doxil ; Doxorubicin ; Doxorubicin - administration & dosage ; Doxorubicin - analogs & derivatives ; Doxorubicin - chemistry ; Doxorubicin - pharmacokinetics ; Female ; Formulations ; Human ; Human placental perfusion ; Humans ; Liposome ; Liposomes ; Low level ; Placenta ; Placenta - cytology ; Placenta - metabolism ; Pregnancy ; Toxicity ; Uptakes</subject><ispartof>Toxicology letters, 2015-12, Vol.239 (2), p.108-114</ispartof><rights>2015 Elsevier Ireland Ltd</rights><rights>Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c428t-9ce57a0cd96eb23f1c204a7d01fd7309ac6647c2975a283a94de62d57245f81d3</citedby><cites>FETCH-LOGICAL-c428t-9ce57a0cd96eb23f1c204a7d01fd7309ac6647c2975a283a94de62d57245f81d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0378427415300515$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26383631$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Soininen, Suvi K.</creatorcontrib><creatorcontrib>Repo, Jenni K.</creatorcontrib><creatorcontrib>Karttunen, Vesa</creatorcontrib><creatorcontrib>Auriola, Seppo</creatorcontrib><creatorcontrib>Vähäkangas, Kirsi H.</creatorcontrib><creatorcontrib>Ruponen, Marika</creatorcontrib><title>Human placental cell and tissue uptake of doxorubicin and its liposomal formulations</title><title>Toxicology letters</title><addtitle>Toxicol Lett</addtitle><description>•Human placental cell and tissue uptake of doxorubicin was significant.•Doxorubicin crossed placenta at low levels within 4-h human placental perfusion.•Pegylated liposomal doxorubicin was weakly taken up by human placental cells.•Pegylated liposomal doxorubicin did not cross human placenta in 4-h perfusion.
The anticancer drug doxorubicin and its liposomal formulations are in clinical use, doxorubicin also during pregnancy. However, little is known about how doxorubicin and its liposomal formulations are taken up by placental cells and whether they can cross human placenta. We therefore investigated quantitative cellular uptake and toxicity of doxorubicin and its two liposomal formulations, pH-sensitive liposomal doxorubicin (L-DOX) and commercially available pegylated liposomal doxorubicin (PL-DOX), in human placental choriocarcinoma (BeWo) cells. PL-DOX showed significantly lower cellular uptake and toxicity compared with doxorubicin and L-DOX. In preliminary studies with human placental perfusion, PL-DOX did not cross the placenta at all in 4h, whereas doxorubicin and L-DOX crossed the placenta at low levels (max 12% of the dose). Furthermore, PL-DOX did not accumulate in placental tissue while doxorubicin did (up to 70% of the dose). Surface pegylation probably explains the low placental cell and tissue uptake of PL-DOX. Formulation of doxorubicin thus seems to enable a decrease of fetal exposure.</description><subject>Antibiotics, Antineoplastic - administration & dosage</subject><subject>Antibiotics, Antineoplastic - pharmacokinetics</subject><subject>BeWo cells</subject><subject>Cell Line, Tumor</subject><subject>Cell Survival</subject><subject>Cellular</subject><subject>Doxil</subject><subject>Doxorubicin</subject><subject>Doxorubicin - administration & dosage</subject><subject>Doxorubicin - analogs & derivatives</subject><subject>Doxorubicin - chemistry</subject><subject>Doxorubicin - pharmacokinetics</subject><subject>Female</subject><subject>Formulations</subject><subject>Human</subject><subject>Human placental perfusion</subject><subject>Humans</subject><subject>Liposome</subject><subject>Liposomes</subject><subject>Low level</subject><subject>Placenta</subject><subject>Placenta - cytology</subject><subject>Placenta - metabolism</subject><subject>Pregnancy</subject><subject>Toxicity</subject><subject>Uptakes</subject><issn>0378-4274</issn><issn>1879-3169</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkE1P3DAURa2qqAy0_6BCWXaT8PwRO94gVQgKEhIbWFse-0XyNImD7SD678kwlGXV1duce6_eIeQ7hYYClee7psSXAUvDgLYN6AYo_UQ2tFO65lTqz2QDXHW1YEock5OcdwAghWy_kGMmecclpxvycLOMdqrmwTqcih0qh8NQ2clXJeS8YLXMxf7GKvaVjy8xLdvgwvQGhJKrIcwxx3HN9TGNy2BLiFP-So56O2T89n5PyeP11cPlTX13_-v28udd7QTrSq0dtsqC81rilvGeOgbCKg-094qDtk5KoRzTqrWs41YLj5L5VjHR9h31_JT8OPTOKT4tmIsZQ94_YCeMSzZUSUZByZb_B8qUXIcAVlQcUJdizgl7M6cw2vTHUDB79WZnDurNXr0BbVb1a-zsfWHZjug_Qn9dr8DFAcBVyXPAZLILODn0IaErxsfw74VX8wyXNQ</recordid><startdate>20151203</startdate><enddate>20151203</enddate><creator>Soininen, Suvi K.</creator><creator>Repo, Jenni K.</creator><creator>Karttunen, Vesa</creator><creator>Auriola, Seppo</creator><creator>Vähäkangas, Kirsi H.</creator><creator>Ruponen, Marika</creator><general>Elsevier Ireland Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7ST</scope><scope>7U7</scope><scope>C1K</scope><scope>SOI</scope><scope>8FD</scope><scope>FR3</scope><scope>KR7</scope></search><sort><creationdate>20151203</creationdate><title>Human placental cell and tissue uptake of doxorubicin and its liposomal formulations</title><author>Soininen, Suvi K. ; Repo, Jenni K. ; Karttunen, Vesa ; Auriola, Seppo ; Vähäkangas, Kirsi H. ; Ruponen, Marika</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c428t-9ce57a0cd96eb23f1c204a7d01fd7309ac6647c2975a283a94de62d57245f81d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Antibiotics, Antineoplastic - administration & dosage</topic><topic>Antibiotics, Antineoplastic - pharmacokinetics</topic><topic>BeWo cells</topic><topic>Cell Line, Tumor</topic><topic>Cell Survival</topic><topic>Cellular</topic><topic>Doxil</topic><topic>Doxorubicin</topic><topic>Doxorubicin - administration & dosage</topic><topic>Doxorubicin - analogs & derivatives</topic><topic>Doxorubicin - chemistry</topic><topic>Doxorubicin - pharmacokinetics</topic><topic>Female</topic><topic>Formulations</topic><topic>Human</topic><topic>Human placental perfusion</topic><topic>Humans</topic><topic>Liposome</topic><topic>Liposomes</topic><topic>Low level</topic><topic>Placenta</topic><topic>Placenta - cytology</topic><topic>Placenta - metabolism</topic><topic>Pregnancy</topic><topic>Toxicity</topic><topic>Uptakes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Soininen, Suvi K.</creatorcontrib><creatorcontrib>Repo, Jenni K.</creatorcontrib><creatorcontrib>Karttunen, Vesa</creatorcontrib><creatorcontrib>Auriola, Seppo</creatorcontrib><creatorcontrib>Vähäkangas, Kirsi H.</creatorcontrib><creatorcontrib>Ruponen, Marika</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Environment Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Environment Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Civil Engineering Abstracts</collection><jtitle>Toxicology letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Soininen, Suvi K.</au><au>Repo, Jenni K.</au><au>Karttunen, Vesa</au><au>Auriola, Seppo</au><au>Vähäkangas, Kirsi H.</au><au>Ruponen, Marika</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Human placental cell and tissue uptake of doxorubicin and its liposomal formulations</atitle><jtitle>Toxicology letters</jtitle><addtitle>Toxicol Lett</addtitle><date>2015-12-03</date><risdate>2015</risdate><volume>239</volume><issue>2</issue><spage>108</spage><epage>114</epage><pages>108-114</pages><issn>0378-4274</issn><eissn>1879-3169</eissn><abstract>•Human placental cell and tissue uptake of doxorubicin was significant.•Doxorubicin crossed placenta at low levels within 4-h human placental perfusion.•Pegylated liposomal doxorubicin was weakly taken up by human placental cells.•Pegylated liposomal doxorubicin did not cross human placenta in 4-h perfusion.
The anticancer drug doxorubicin and its liposomal formulations are in clinical use, doxorubicin also during pregnancy. However, little is known about how doxorubicin and its liposomal formulations are taken up by placental cells and whether they can cross human placenta. We therefore investigated quantitative cellular uptake and toxicity of doxorubicin and its two liposomal formulations, pH-sensitive liposomal doxorubicin (L-DOX) and commercially available pegylated liposomal doxorubicin (PL-DOX), in human placental choriocarcinoma (BeWo) cells. PL-DOX showed significantly lower cellular uptake and toxicity compared with doxorubicin and L-DOX. In preliminary studies with human placental perfusion, PL-DOX did not cross the placenta at all in 4h, whereas doxorubicin and L-DOX crossed the placenta at low levels (max 12% of the dose). Furthermore, PL-DOX did not accumulate in placental tissue while doxorubicin did (up to 70% of the dose). Surface pegylation probably explains the low placental cell and tissue uptake of PL-DOX. Formulation of doxorubicin thus seems to enable a decrease of fetal exposure.</abstract><cop>Netherlands</cop><pub>Elsevier Ireland Ltd</pub><pmid>26383631</pmid><doi>10.1016/j.toxlet.2015.09.011</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0378-4274 |
| ispartof | Toxicology letters, 2015-12, Vol.239 (2), p.108-114 |
| issn | 0378-4274 1879-3169 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1762107653 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Antibiotics, Antineoplastic - administration & dosage Antibiotics, Antineoplastic - pharmacokinetics BeWo cells Cell Line, Tumor Cell Survival Cellular Doxil Doxorubicin Doxorubicin - administration & dosage Doxorubicin - analogs & derivatives Doxorubicin - chemistry Doxorubicin - pharmacokinetics Female Formulations Human Human placental perfusion Humans Liposome Liposomes Low level Placenta Placenta - cytology Placenta - metabolism Pregnancy Toxicity Uptakes |
| title | Human placental cell and tissue uptake of doxorubicin and its liposomal formulations |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T02%3A20%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Human%20placental%20cell%20and%20tissue%20uptake%20of%20doxorubicin%20and%20its%20liposomal%20formulations&rft.jtitle=Toxicology%20letters&rft.au=Soininen,%20Suvi%20K.&rft.date=2015-12-03&rft.volume=239&rft.issue=2&rft.spage=108&rft.epage=114&rft.pages=108-114&rft.issn=0378-4274&rft.eissn=1879-3169&rft_id=info:doi/10.1016/j.toxlet.2015.09.011&rft_dat=%3Cproquest_cross%3E1762107653%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1727697500&rft_id=info:pmid/26383631&rft_els_id=S0378427415300515&rfr_iscdi=true |